203 related articles for article (PubMed ID: 38012197)
1. Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach.
Oron-Herman M; Kirmayer D; Lupp A; Schulz S; Kostenich G; Afargan M
Sci Rep; 2023 Nov; 13(1):20857. PubMed ID: 38012197
[TBL] [Abstract][Full Text] [Related]
2. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S
Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506
[TBL] [Abstract][Full Text] [Related]
3. A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas.
Körner M; Waser B; Christ E; Beck J; Reubi JC
Neuroendocrinology; 2018; 106(2):116-127. PubMed ID: 28384628
[TBL] [Abstract][Full Text] [Related]
4. Comparison of somatostatin receptor expression in human gliomas and medulloblastomas.
Cervera P; Videau C; Viollet C; Petrucci C; Lacombe J; Winsky-Sommerer R; Csaba Z; Helboe L; Daumas-Duport C; Reubi JC; Epelbaum J
J Neuroendocrinol; 2002 Jun; 14(6):458-71. PubMed ID: 12047721
[TBL] [Abstract][Full Text] [Related]
5. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
[TBL] [Abstract][Full Text] [Related]
6. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of expression of somatostatin receptor 1, 2, 3, 5 and dopamine D2 receptor in spindle cell oncocytomas of posterior pituitary.
Soukup J; Kasparova P; Kohout A; Rychly B; Skarkova V; Syrucek M; Gabalec F
Pituitary; 2019 Feb; 22(1):70-78. PubMed ID: 30607746
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
9. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?
Körner M; Waser B; Reubi JC
Neuroendocrinology; 2015; 101(1):45-57. PubMed ID: 25591947
[TBL] [Abstract][Full Text] [Related]
10. A Somatostatin Receptor Subtype-3 (SST
Vázquez-Borrego MC; Gupta V; Ibáñez-Costa A; Gahete MD; Venegas-Moreno E; Toledano-Delgado Á; Cano DA; Blanco-Acevedo C; Ortega-Salas R; Japón MA; Barrera-Martín A; Vasiljevic A; Hill J; Zhang S; Halem H; Solivera J; Raverot G; Gálvez MA; Soto-Moreno A; Paez-Pereda M; Culler MD; Castaño JP; Luque RM
Clin Cancer Res; 2020 Feb; 26(4):957-969. PubMed ID: 31624102
[TBL] [Abstract][Full Text] [Related]
11. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells.
Carrere N; Vernejoul F; Souque A; Asnacios A; Vaysse N; Pradayrol L; Susini C; Buscail L; Cordelier P
Hum Gene Ther; 2005 Oct; 16(10):1175-93. PubMed ID: 16218779
[TBL] [Abstract][Full Text] [Related]
14. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
15. Expression and localisation of somatostatin receptor subtypes sst1-sst5 in areas of the rat medulla oblongata involved in autonomic regulation.
Spary EJ; Maqbool A; Batten TF
J Chem Neuroanat; 2008 Jan; 35(1):49-66. PubMed ID: 17646081
[TBL] [Abstract][Full Text] [Related]
16. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.
Asnacios A; Courbon F; Rochaix P; Bauvin E; Cances-Lauwers V; Susini C; Schulz S; Boneu A; Guimbaud R; Buscail L
J Clin Oncol; 2008 Feb; 26(6):963-70. PubMed ID: 18281671
[TBL] [Abstract][Full Text] [Related]
17. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Baum RP; Prasad V; Hommann M
Int J Clin Exp Pathol; 2012; 5(3):187-94. PubMed ID: 22558472
[TBL] [Abstract][Full Text] [Related]
18. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment.
Reubi JC
Neuroendocrinology; 2004; 80 Suppl 1():51-6. PubMed ID: 15477718
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.
Specht E; Kaemmerer D; Sänger J; Wirtz RM; Schulz S; Lupp A
Histopathology; 2015 Sep; 67(3):368-77. PubMed ID: 25641082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
